For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome

We use cookies to make our site as useful as possible.

Our Cookie Policy explains how you can opt-out of the cookies we use.

If you continue without changing your cookie settings, we'll assume you’re happy with this.

Continue Continue

United States
Your country/region is currently set to:

If incorrect, please enter your country/region into the box below, to view site information related to your country/region.

Call (888) 77-ABCAM (22226) or contact us
Need help? Contact us

  • My account
  • Sign out
Sign in or Register with us

Welcome

Sign in or

Don't have an account?

Register with us
My basket
Quick order
Abcam homepage

  • Research Products
    By product type
    Primary antibodies
    Secondary antibodies
    ELISA and Matched Antibody Pair Kits
    Cell and tissue imaging tools
    Cellular and biochemical assays
    Proteins and Peptides
    By product type
    Proteomics tools
    Agonists, activators, antagonists and inhibitors
    Cell lines and Lysates
    Multiplex miRNA assays
    Multiplex Assays
    By research area
    Cancer
    Cardiovascular
    Cell Biology
    Epigenetics
    Metabolism
    Developmental Biology
    By research area
    Immunology
    Microbiology
    Neuroscience
    Signal Transduction
    Stem Cells
  • Diagnostic & Therapeutic Solutions
    Custom solutions & partnerships

    Custom antibody development and commercial partnerships to advance your diagnostic and therapeutic discovery.

    Create custom solutions with us

    Partner with us

  • Support
    Support hub

    Access advice and support for any research roadblock

    View support hub

    Protocols

    Your experiments laid out step by step

    View protocols

  • Events
    • Conference calendar
    • Cancer
    • Cardiovascular
    • Epigenetics & Nuclear signaling
    • Immunology
    • Neuroscience
    • Stem cells
    • Tradeshows
    • Scientific webinars
    Keep up to date with the latest events

    Full event breakdown with abstracts, speakers, registration and more

    View global event calendar

  • Pathways
    Cell signalling pathways

    View all pathways

    View all interactive pathways

Supporting our customers and employees during the COVID-19 pandemic. Read more

Prostate cancer biomarkers

Related

  • Cancer biomarker guide
    • IHC guide
      • Epithelial-to-mesenchymal transition
        • Studying the hallmarks of cancer

          Find the right cancer biomarker for your research using our cancer immunohistochemistry (IHC) guide to prostate cancer

          Prostate cancer is the second most common cancer in men worldwide. IHC is used for diagnosis from prostate biopsy, though this remains controversial as to the precision and accuracy of the current biomarkers used in this test and many are looking for alternative specific and sensitive prostate cancer biomarkers to improve outcomes. (Jiang et al. 2013).

          While a panel of IHC prostate cancer biomarkers are commonly used for prostate cancer diagnosis (including PSA, AMACR and high molecular weight cytokeratins), issues around benign tumors mimicking this profile and the early detection of presence and progression of prostate cancer, and recurrence following clinical intervention are still not accurately validated by current biomarkers for prostate cancer.

          There remains a lack of reliable biomarkers to accurately predict low-risk cancer and avoid overtreatment. As such, aggressive forms of prostate cancer may be missed and indolent disease may be subjected to unnecessary radical therapy. New biomarker discovery and validation promise to improve early detection and prognosis and to provide targets for therapeutic interventions (Giannico et al. 2017).

          Overview

          • Primary IHC prostate cancer biomarkers
          • Cell type biomarkers


          Primary IHC prostate cancer biomarkers​
          Prostate Specific Antigen (PSA)

          PSA is the most widely known biomarker for prostate cancer. It is expressed in prostate epithelial cells and secreted to the seminal fluid where it plays a role in its liquefaction. PSA is considered to be a highly sensitive and specific biomarker for prostate tumors. It was approved by the FDA for diagnosis of prostate cancer in conjunction with digital rectal exam in 1994. Consequently, the detection of PSA in additional tissues via IHC is typically associated with metastatic cancer of prostatic origin and the presence of this biomarker is often used to differentiate between prostatic and urothelial carcinomas (Saini, 2016).

          Formalin-fixed paraffin-embedded human prostate carcinoma sections stained for Prostate Specific Antigen antibody [EP1588Y] (ab76113) at 1/100 dilution, in immunohistochemical analysis.

          IHC stain: cytoplasmic and extracellular
          Recommended IHC antibody: Recombinant Anti-Prostate Specific Antigen antibody [EP1588Y] (ab76113)


          Alpha-methylacyl-CoA racemase (AMACR)

          AMACR is a mitochondrial and peroxisomal enzyme that functions to oxidize fatty acids and bile acid intermediates. It is over-expressed in the epithelium of approximately 80% of prostate cancer cases, and acts as a robust biomarker of prostate cancer. Detection of AMACR via IHC has been shown to be important in the differential diagnosis of prostate carcinoma from benign prostate mimics. AMACR overexpression in prostate cells is indicative of poor patient prognosis, associated with a high Gleason’s score, high initial PSA levels, and indicative of the increased chance of bone metastasis (El kassem et al., 2016).